Kangjie Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kangjie Xu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ann Marie Egloff
Brigham and Women's Hospital, Boston, MA, United States
35 shared publications - Atrayee Bhattacharya
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
35 shared publications - Atsushi Fushimi
Division of Breast and Endocrine Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan
35 shared publications - Ayako Nakashoji
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
35 shared publications - Donald Kufe
Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts
35 shared publications - Hiroki Ozawa
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
35 shared publications
Latest Publications
- Open Access
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
Regulation of ∆Np63 expression in HSC3 cells.
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
Regulation of ∆Np63 expression in HSC3 cells.
- Open Access
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Data from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
The MUC1-C protein is aberrantly expressed in adenocarcinomas of epithelial barrier tissues and contributes to their progression. Less is known about involvement of MUC1-C in the pathogenesis of squamous cell carcinomas (SCC). Here, we report that the MUC1 gene is upregulated in advanced head and neck SCCs (HNSCC). Studies of HNSCC cell lines demonstrate that the MUC1-C subunit regulates expression of (i) RIG-I and MDA5 pattern recognition receptors, (ii) STAT1 and IFN regulatory factors, and (iii) downstream IFN-stimulated genes. MUC1-C integrates chronic activation of the STAT1 inflammatory pathway with induction of the ∆Np63 and SOX2 genes that are aberrantly expressed in HNSCCs. In extending those dependencies, we demonstrate that MUC1-C is necessary for NOTCH3 expression, self-renewal capacity, and tumorigenicity. The findings that MUC1 associates with ∆Np63, SOX2 and NOTCH3 expression by single-cell RNA sequencing analysis further indicate that MUC1-C drives the HNSCC stem cell state and is a target for suppressing HNSCC progression.Significance:This work reports a previously unrecognized role for MUC1-C in driving STAT1-mediated chronic inflammation with the progression of HNSCC and identifies MUC1-C as a druggable target for advanced HNSCC treatment.
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
The MUC1-C protein is aberrantly expressed in adenocarcinomas of epithelial barrier tissues and contributes to their progression. Less is known about involvement of MUC1-C in the pathogenesis of squamous cell carcinomas (SCC). Here, we report that the MUC1 gene is upregulated in advanced head and neck SCCs (HNSCC). Studies of HNSCC cell lines demonstrate that the MUC1-C subunit regulates expression of (i) RIG-I and MDA5 pattern recognition receptors, (ii) STAT1 and IFN regulatory factors, and (iii) downstream IFN-stimulated genes. MUC1-C integrates chronic activation of the STAT1 inflammatory pathway with induction of the ∆Np63 and SOX2 genes that are aberrantly expressed in HNSCCs. In extending those dependencies, we demonstrate that MUC1-C is necessary for NOTCH3 expression, self-renewal capacity, and tumorigenicity. The findings that MUC1 associates with ∆Np63, SOX2 and NOTCH3 expression by single-cell RNA sequencing analysis further indicate that MUC1-C drives the HNSCC stem cell state and is a target for suppressing HNSCC progression.Significance:This work reports a previously unrecognized role for MUC1-C in driving STAT1-mediated chronic inflammation with the progression of HNSCC and identifies MUC1-C as a druggable target for advanced HNSCC treatment.
- Open Access
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 5 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
MUC1-C/STAT1 signaling regulates activation of the SOX2 gene. A, CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were analyzed for SOX2 gene transcription (left) and mRNA (right) levels. The results (mean ± SD of four determinations) are expressed as relative levels compared with that obtained for vehicle-treated cells (assigned a value of 1). B, CAL27/CshRNA and CAL27/STAT1shRNA cells were analyzed for SOX2 gene transcription (left) and mRNA (right) levels. The results (mean ± SD of four determinations) are expressed as relative levels compared with that obtained for vehicle-treated cells (assigned a value of 1). C, Schema of the SOX2 gene with highlighting localization of the PLS region that contains STAT1 binding motifs. D, Soluble chromatin from CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with anti-MUC1-C and anti-STAT1. The DNA samples were amplified by qPCR with primers for the SOX2 PLS region. The results (mean ± SD of three determinations) are expressed as percentage of input DNA for each sample. E, Lysates from CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. F, Lysates from CAL27/CshRNA and CAL27/STAT1shRNA cells were immunoblotted with antibodies against the indicated proteins.
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 5 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
MUC1-C/STAT1 signaling regulates activation of the SOX2 gene. A, CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were analyzed for SOX2 gene transcription (left) and mRNA (right) levels. The results (mean ± SD of four determinations) are expressed as relative levels compared with that obtained for vehicle-treated cells (assigned a value of 1). B, CAL27/CshRNA and CAL27/STAT1shRNA cells were analyzed for SOX2 gene transcription (left) and mRNA (right) levels. The results (mean ± SD of four determinations) are expressed as relative levels compared with that obtained for vehicle-treated cells (assigned a value of 1). C, Schema of the SOX2 gene with highlighting localization of the PLS region that contains STAT1 binding motifs. D, Soluble chromatin from CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with anti-MUC1-C and anti-STAT1. The DNA samples were amplified by qPCR with primers for the SOX2 PLS region. The results (mean ± SD of three determinations) are expressed as percentage of input DNA for each sample. E, Lysates from CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. F, Lysates from CAL27/CshRNA and CAL27/STAT1shRNA cells were immunoblotted with antibodies against the indicated proteins.
- Open Access
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 6 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
MUC1-C regulates NOTCH3 expression and HNSCC cell self-renewal capacity. A, CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were analyzed for NOTCH3 mRNA levels. The results (mean ± SD of four determinations) are expressed as relative levels compared with that obtained for vehicle-treated cells (assigned a value of 1; left). Lysates were immunoblotted with antibodies against the indicated proteins (right). B, GSEA of RNA-seq data from CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days using the REACTOME SIGNALING BY NOTCH3 gene signature. C, The indicated CAL27 cells treated with vehicle or DOX for 7 days were analyzed for tumorsphere formation. Shown are representative images of the tumorspheres (bar represents 100 µm). SFE is expressed as the mean ± SD of three independent replicates relative to that obtained for vehicle-treated cells (assigned a value of 1). D, Lysates from CAL27 cells treated with vehicle or 5 µmol/L GO-203 for 3 days were immunoblotted with antibodies against the indicated proteins. E, CAL27 cells were treated with vehicle or 5 µmol/L GO-203 while they were analyzed for colony formation. Shown are representative photomicrographs of stained colonies (left). The results (mean ± SD of three determinations) are expressed as relative colony formation compared with that for vehicle-treated cells (assigned a value of 1; right). F, CAL27 cells were treated with vehicle or 5 µmol/L GO-203 while they were analyzed for tumorsphere formation. Shown are representative images of the tumorspheres (bar represents 100 µm). SFE is expressed as the mean ± SD of three independent replicates relative to that obtained for untreated cells (assigned a value of 1). G and H, Six-week-old nude mice were injected subcutaneously in the flank with 1 × 107 CAL27 cells. Mice pair-matched into groups of 5 mice each when tumors reached 100–150 mm3 were treated with vehicle control or GO-203 for the indicated days. Tumor volumes are expressed as the mean ± SEM for 5 mice (G). Lysates from control and GO-203–treated tumors were immunoblotted with antibodies against the indicated proteins (H).
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 6 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
MUC1-C regulates NOTCH3 expression and HNSCC cell self-renewal capacity. A, CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were analyzed for NOTCH3 mRNA levels. The results (mean ± SD of four determinations) are expressed as relative levels compared with that obtained for vehicle-treated cells (assigned a value of 1; left). Lysates were immunoblotted with antibodies against the indicated proteins (right). B, GSEA of RNA-seq data from CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days using the REACTOME SIGNALING BY NOTCH3 gene signature. C, The indicated CAL27 cells treated with vehicle or DOX for 7 days were analyzed for tumorsphere formation. Shown are representative images of the tumorspheres (bar represents 100 µm). SFE is expressed as the mean ± SD of three independent replicates relative to that obtained for vehicle-treated cells (assigned a value of 1). D, Lysates from CAL27 cells treated with vehicle or 5 µmol/L GO-203 for 3 days were immunoblotted with antibodies against the indicated proteins. E, CAL27 cells were treated with vehicle or 5 µmol/L GO-203 while they were analyzed for colony formation. Shown are representative photomicrographs of stained colonies (left). The results (mean ± SD of three determinations) are expressed as relative colony formation compared with that for vehicle-treated cells (assigned a value of 1; right). F, CAL27 cells were treated with vehicle or 5 µmol/L GO-203 while they were analyzed for tumorsphere formation. Shown are representative images of the tumorspheres (bar represents 100 µm). SFE is expressed as the mean ± SD of three independent replicates relative to that obtained for untreated cells (assigned a value of 1). G and H, Six-week-old nude mice were injected subcutaneously in the flank with 1 × 107 CAL27 cells. Mice pair-matched into groups of 5 mice each when tumors reached 100–150 mm3 were treated with vehicle control or GO-203 for the indicated days. Tumor volumes are expressed as the mean ± SEM for 5 mice (G). Lysates from control and GO-203–treated tumors were immunoblotted with antibodies against the indicated proteins (H).
- Open Access
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
Effects of targeting MUC1-C on effectors of the type I and II IFN pathways.
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
Effects of targeting MUC1-C on effectors of the type I and II IFN pathways.
- Open Access
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
Effects of silencing MUC1-C on HNSCC cell clonogenic survival.
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
Effects of silencing MUC1-C on HNSCC cell clonogenic survival.
- Open Access
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 7 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
Single-cell profiling of the expression of MUC1 and related genes in HNSCC. A–C, UMAP representation of total cells analyzed from the GSE118389 dataset of HPV-negative/HPV-positive HNSCC samples (A), GSE118389 dataset of HPV-negative samples (B), and GSE118389 dataset of HPV-positive samples (C) (left). Distributions of MUC1 expression in individual cells (middle). MUC1 expression in individual cells in each cell type (right). D, Model depicting the current findings that MUC1-C integrates activation of STAT1, IFN type I/II signaling and ISG expression with regulation of ∆Np63, SOX2, and NOTCH3 in driving the HNSCC CSC state that promotes DNA damage resistance and immune evasion.
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 7 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
Single-cell profiling of the expression of MUC1 and related genes in HNSCC. A–C, UMAP representation of total cells analyzed from the GSE118389 dataset of HPV-negative/HPV-positive HNSCC samples (A), GSE118389 dataset of HPV-negative samples (B), and GSE118389 dataset of HPV-positive samples (C) (left). Distributions of MUC1 expression in individual cells (middle). MUC1 expression in individual cells in each cell type (right). D, Model depicting the current findings that MUC1-C integrates activation of STAT1, IFN type I/II signaling and ISG expression with regulation of ∆Np63, SOX2, and NOTCH3 in driving the HNSCC CSC state that promotes DNA damage resistance and immune evasion.
- Open Access
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
Primers used for qRT-PCR analysis.
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
Primers used for qRT-PCR analysis.
- Open Access
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
MUC1-C/STAT1 signaling regulates ∆Np63 expression. A, CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were analyzed for ∆Np63 gene transcription (left) and mRNA (right) levels. The results (mean ± SD of four determinations) are expressed as relative levels compared with that obtained for vehicle-treated cells (assigned a value of 1). B, CAL27/CshRNA and CAL27/STAT1shRNA cells were analyzed for ∆Np63 gene transcription (left) and mRNA (right) levels. The results (mean ± SD of four determinations) are expressed as relative levels compared with that obtained for vehicle-treated cells (assigned a value of 1). C, Schema of the ∆Np63 gene with highlighting localization of the PLS region that contains potential STAT1 binding motifs. D, Soluble chromatin from CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with anti-MUC1-C and anti-STAT1. The DNA samples were amplified by qPCR with primers for the ∆Np63 PLS region. The results (mean ± SD of three determinations) are expressed as percentage of the input DNA for each sample. E, CAL27 cells expressing the indicated vectors were treated with vehicle or DOX for 7 days. Lysates were immunoblotted with antibodies against the indicated proteins. F, Lysates from CAL27/CshRNA and CAL27/STAT1shRNA cells were immunoblotted with antibodies against the indicated proteins.
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
MUC1-C/STAT1 signaling regulates ∆Np63 expression. A, CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were analyzed for ∆Np63 gene transcription (left) and mRNA (right) levels. The results (mean ± SD of four determinations) are expressed as relative levels compared with that obtained for vehicle-treated cells (assigned a value of 1). B, CAL27/CshRNA and CAL27/STAT1shRNA cells were analyzed for ∆Np63 gene transcription (left) and mRNA (right) levels. The results (mean ± SD of four determinations) are expressed as relative levels compared with that obtained for vehicle-treated cells (assigned a value of 1). C, Schema of the ∆Np63 gene with highlighting localization of the PLS region that contains potential STAT1 binding motifs. D, Soluble chromatin from CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with anti-MUC1-C and anti-STAT1. The DNA samples were amplified by qPCR with primers for the ∆Np63 PLS region. The results (mean ± SD of three determinations) are expressed as percentage of the input DNA for each sample. E, CAL27 cells expressing the indicated vectors were treated with vehicle or DOX for 7 days. Lysates were immunoblotted with antibodies against the indicated proteins. F, Lysates from CAL27/CshRNA and CAL27/STAT1shRNA cells were immunoblotted with antibodies against the indicated proteins.
- Open Access
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
Regulation of SOX2 expression in HSC3 cells.
- 14 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas
Regulation of SOX2 expression in HSC3 cells.